Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
61-75 of 3890 results
Janssen, USAID to expand access to anti-multidrug-resistant tuberculosis compound
By PBR Staff Writer
Johnson & Johnson's affiliate Janssen Therapeutics has signed a Memorandum of Understanding (MOU) with the US Agency for International Development (USAID) to fight against the antibiotic-resistant bacteria threat.
Drug Research > Drug Discovery & Development > News
Bayer and DNDi to develop an innovative oral treatment for human river blindness
Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis).
Drug Research > Drug Discovery & Development > News
FDA accepts Boston's IND to begin clinical trial of BTI-320 to treat type 2 diabetes and weight loss
By PBR Staff Writer
The US Food and Drug Administration (FDA) has accepted Boston Therapeutics' investigational new drug (IND) application to start a clinical trial of BTI-320 to treat type 2 diabetes and weight management.
Drug Research > Drug Discovery & Development > News
Spark Therapeutics, Pfizer to develop new treatment paradigm for hemophilia B
By PBR Staff Writer
US-based Spark Therapeutics has entered into a global collaboration with Pfizer to develop and commercialize SPK-FIX, a development program advancing proprietary, bio-engineered adeno-associated virus (AAV) vectors for the potential treatment of hemophilia B.
Drug Research > Drug Discovery & Development > News
Amgen initiates Phase I trial of melanoma drug combination
By PBR Staff Writer
US-based Amgen has commenced a Phase I trial of talimogene laherparepvec, an investigational oncolytic immunotherapy, for the treatment of patients with regionally or distantly metastatic melanoma.
Drug Research > Drug Discovery & Development > News
Novo Nordisk reports positive results from phase III trial of NovoEight in haemophilia A people
Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest annualised bleeding rate (ABR) during initial treatment with NovoEight (turoctocog alfa) showed the largest reduction in bleeding over the duration of treatment.
Drug Research > Drug Discovery & Development > News
AbbVie releases results from phase II study of venetoclax in acute myelogenous Leukemia
AbbVie presented during an oral presentation at the American Society of Hematology's 56th Annual Meeting new results from a Phase 2 study of investigational compound venetoclax (ABT-199/GDC-0199) in patients with acute myelogenous leukemia (AML).
Drug Research > Drug Discovery & Development > News
Seattle Genetics, Takeda report phase III AETHERA clinical trial data from ADCETRIS
Seattle Genetics, and Takeda Pharmaceutical Company reported data demonstrating that Hodgkin lymphoma (HL) patients at risk of relapse following an autologous stem cell transplant (ASCT) who received ADCETRIS (brentuximab vedotin) as consolidation therapy immediately after ASCT had significant improvement in progression-free survival (PFS) compared to patients who received placebo (median of 43 months versus 24 months, respectively; hazard ratio=0.57; p-value=0.001).
Drug Research > Drug Discovery & Development > News
ImmunoCellular gets EMA positive regulatory feedback on advancing ICT-107 to phase III program
ImmunoCellular Therapeutics announced that the European Medicines Agency (EMA) has provided scientific advice supportive of advancing ICT-107 to a registrational phase III program in patients with newly diagnosed glioblastoma (GBM).
Drug Research > Drug Discovery & Development > News
The Medicines Patent Pool signs licensing deal with AbbVie for HIV paediatric formulations
On World AIDS Day, the Medicines Patent Pool and AbbVie announced a licensing agreement for lopinavir (LPV) and ritonavir (r), top World Health Organization-recommended medicines for children.
Drug Research > Drug Discovery & Development > News
ViiV Healthcare secures new grants in support of ending mother to child transmission of HIV
The Positive Action for Children Fund (PACF) is proud to announce 103 grants for 2015 totalling £5 million. 54 new grants and 49 extensions will be funded to support community responses to help end mother to child transmission of HIV thereby delivering crucial services to mothers, children and HIV affected families.
Drug Research > Drug Discovery & Development > News
Dynavax regains complete rights to TLR 7/9 Inhibitor DV1179
By PBR Staff Writer
Dynavax Technologies has regained full rights to DV1179, an investigational bifunctional inhibitor of toll-like receptors (TLR) 7 and 9, after the expiration of the research and development (R&D) collaboration and license deal with GlaxoSmithKline (GSK).
Drug Research > Drug Discovery & Development > News
Oxford and Menarini begins first-in-human trial of leukemia drug OBT357
By PBR Staff Writer
Oxford BioTherapeutics and Menarini Group have started the first-in-human clinical trial of OBT357 (MEN1112), a new improved antibody to treat acute myeloid leukemia (AML).
Drug Research > Drug Discovery & Development > News
AstraZeneca's Duaklir Genuair gets marketing approval in Europe for COPD
By PBR Staff Writer
AstraZeneca has received marketing authorisation from the European Commission (EC) for its Duaklir Genuair (aclidinium bromide/formoterol fumarate 340/12mcg) to be used as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Drug Research > Drug Discovery & Development > News
ZS Pharma reports results from Phase III study of ZS-9 in patients with hyperkalemia
ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, announced the publication of previously unreleased detailed results from the ZS003 study in the New England Journal of Medicine (NEJM).
Drug Research > Drug Discovery & Development > News
61-75 of 3890 results